Nasal decongestant activity of pseudoephedrine.
The effectiveness of orally administered pseudoephedrine in patients with acute or chronic nonsuppurative rhinitis was evaluated under double-blind conditions. Intranasally administered ephedrine which was given to all patients at the end of this study served as the positive control. Marked nasal decongestant effects of a single oral dose of pseudoephedrine (60 mg tablet), as determined by a modified passive anterior, rhinometric technique occurred within 30 minutes and were maintained for at least four hours. The mean nasal decongestant response (delta % of baseline) of 57.2% was associated with a mean peak, plasma pseudoephedrine level of 274 ng/ml. In addition, the maximum response to oral pseudoephedrine treatment was equivalent to the response produced by ephedrine nasal spray. These results suggest that pseudoephedrine is an orally, effective nasal decongestant.
D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000403:Airway Resistance / Q000187:drug effects; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004809:Ephedrine / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009666:Nose / Q000503:physiopathology; D010919:Placebos; D011312:Pressure; D012220:Rhinitis / Q000097:blood / Q000188:drug therapy*
D000336:Aerosols; D010919:Placebos; D004809:Ephedrine